Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

Adenocarcinoma
Neversmoking

EGFR Exon 20
Insertions

EGFR Mutant
(Not Exon 20)

LUN0112
Phase II
Carboplatin +
Pemetrexed +
Bevacizumab
+/-
Atezolizumab
in Stage IV
Non-Squamous
NSCLC
Pt: Wakelee
NCTN

LUN0113
Phase III TAK-788
First-Line Tx vs
Platinum-Based
Chemo in NSCLC w/
EGFR Exon 20
Insertion Mutations
Pt: Neal
Sponsor: Takeda

ECOG-ACRIN-
EA5182
Randomized Phase III
Study of Combination
Osimertinib
(AZD9291) and
Bevacizumab versus
Osimertinib
(AZD9291) Alone as
First-Line Treatment
in Metastatic
EGFR-Mutant NSCLC
Pt: Neal
Sponsor: ECOG-ACRIN

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu